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Editorial for Pharmacoeconomics: Capturing the impact of direct treatment disutility.   
 
 
Do pills have no ills? Capturing the impact of direct treatment 
disutility 
 
1. Introduction 
 
Model-based economic evaluations of interventions should capture the impact on all the costs 
and outcomes relevant to the chosen study perspective and time horizon. In a number of 
jurisdictions, the quality adjusted life year (QALY) is the recommended measure of benefit 
given its potential to capture both quantity and health-related quantity of life in a single 
metric [1]. When calculating QALYs, the impact on health-related quality of life is valued 
using utility values, which are sourced from preference-based exercises, and then attached to 
specified condition-related health states or, where relevant, adverse drug reactions. In 
general, taking the medicine itself is assumed to cause no inconvenience to the patient, or in 
other words, have no direct treatment disutility. This editorial will define what is meant by 
direct treatment disutility and highlight why it is an important attribute which should be 
considered for integration within model-based economic evaluations, particularly for 
medicines used for primary prevention that require patients to take a daily pill for very long 
periods for relatively small lifetime benefits.  
 
2. Direct treatment disutility 
The traditional approach in economic theory is to assign no overall value to the direct impact 
of the healthcare intervention. Instead the value is derived from the subsequent health-related 
outcomes reflecting the use of those interventions. This impact on health-related outcomes 
can be positive or negative (reflecting the impact of adverse treatment effects).This focus on 
health-related outcomes has been criticised as being narrowly consequentialist [2]. By 
focusing attention entirely on the subsequent health-related outcomes, some key attributes 
which patients may value are missed. The useful concept of process utility has been put 
forward [3] as the means to think about attributes of an intervention, like the way in which 
healthcare information is delivered or maintaining dignity, which may not affect the final 
health outcome but which are still valued by patients.  
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There is also the potential for interventions to have negative attributes associated with their 
use. Obvious examples of such interventions are those which are invasive such as surgical 
procedures, screening programmes and biopsies. In addition, interventions which place a 
considerable burden on patients such as the need to undergo frequent injections or routinely 
attend a clinic, to have chemotherapy or a biologic administered, may have negative process 
utility. Brennan and Dixon provide a useful systematic review of such process utilities [4].  
In this editorial we highlight the potential relevance of direct treatment disutility (hereafter 
termed DTD). Our focus is on long-term medication use, such as statins for the primary 
prevention of cardiovascular disease, which requires daily treatment over many years for 
benefits to be realised and translated into health gain. Taking statins would generally be 
considered to be non-invasive in the traditional sense and is believed to have low day-to-day 
treatment burden on patients. However, with a relatively small absolute benefit from 
treatment which accrues over very long periods, patient preferences regarding use of the 
medicine over a life-time could be important in determining patients’ take-up of the 
intervention [5,6] as well as its cost-effectiveness. 
For a particular medicine we define direct treatment disutility as representing an individuals’ 
strength of preference for not taking the medicine, which may arise for a number of reasons. 
Patients are likely to value negatively the inconvenience of obtaining prescriptions and 
collecting the medicine from pharmacies, taking it every day and then having to undergo 
ongoing maintenance in terms of visiting general practitioners and other health care 
professionals for monitoring. For some patients the requirement to take an intervention for 
life is an unpalatable prospect in its own right. Preventative medicines do also have the 
potential for adverse drug reactions or out-of-pocket costs but these attributes are outside of 
our definition of DTDs as there are other mechanisms by which these attributes can be 
included within decision-models. DTDs are possible for a range of interventions and do not 
specifically have to be associated with a medicine. There is no reason why the concept of 
DTD could not be extended to other interventions. However, here we focus on DTDs 
associated with long-term medication use because there is evidence that even small DTDs 
when they occur over a long period are likely be important for cost-effectiveness. 
Our rationale for suggesting the term DTD as a subset of process utility is to make clear the 
obvious negative value associated directly with the use of a medicine in general, and a long-
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term preventative medicine in particular. Previous efforts to identify process utility studies in 
the literature have been hindered by a lack of consistent terminology and indexing [4], and 
the use of the term DTD would facilitate easier sourcing of values from the literature for 
inclusion in future decision models.  
3. Current evidence from the literature 
A rapid review of the literature was conducted on 1st July 2015, using a parsimonious search 
strategy (available on request) in four databases (Medline, Embase, PsyINFO and Econlit) in 
OVID. We sought to find studies which elicited DTDs from patients or the general public, 
and evidence on the use of treatment disutilities included within model-based CEAs for 
statins for prevention of cardiovascular disease or with a focus on cardiovascular disease. We 
chose this exemplar case because with falling costs of statins as they come off patent, new 
clinical guidelines including the one published by the National Institute for Health and Care 
Excellence (NICE) in 2014 are recommending their use in people at much lower levels of 
baseline risk of cardiovascular disease [7], in whom absolute benefit over a lifetime of 
treatment is relatively small. In this context, DTD may therefore have significant impact on 
the overall relative cost-effectiveness of the healthcare intervention.  
 
3.1 Elicitation of DTDs 
Three published empirical studies that relate to the concept of DTD were identified through 
the search strategy [6,8,9]; and one was found via reference list searching [10]. Gage et al 
find a disutility directly associated with taking warfarin of 0.003 and no disutility associated 
with taking aspirin when using a time-trade off method in patients (n=70) with atrial 
fibrillation [10]. More recently, using time trade off (TTO) methods to elicit values, Hutchins 
et al found DTDs of 0.01 (95% CI: 0.008 to 0.013) in US residents (n=1000) and 0.003 (95% 
CI: 0.002 to 0.004) in US healthcare employees (n=708) for a scenario involving one pill per 
day for life which had no costs or side effects [8,9]. In both papers, standard gamble and 
willingness to pay methods were also used to elicit disutilities and gave comparable results.  
 
Fontana et al (2014) use DTD values to inform a patient-accessible tool to encourage shared 
decision-making. They use a TTO method and find that two-thirds of the general public 
interviewed in London (n=360) would require a gain of more than one-month at the end of 
life in order for them to be willing to take a pill per day for life. For a perfect pill with no 
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ongoing maintenance or side effects, that would represent a DTD of at least 0.00274 per year 
if patients were assumed to live for another 30 years.  
 
All four papers find significant heterogeneity in the preferences of the participants. For 
example, Fontana finds evidence of individuals with ‘extreme’ values of DTD who would 
require greater than 10-years life-gain to take a tablet every day (a DTD of approximately 
0.033) whilst there is also evidence of a class of individuals who would only need less than 1-
month of extra-life in order to undergo treatment (a DTD of near-zero). Hutchins et al (2014) 
also finds evidence of class of reluctant pill-takers with 30% of their sample being willing to 
trade time versus 70% of their sample being unwilling to trade any time at all (equivalent to a 
DTD of zero). 
 
3.2 Inclusion of DTDs in model-based economic evaluations  
Model-based evaluations provide a structured and explicit framework in which to synthesise 
data inputs, including potential DTDs, from a range of sources within the same analysis [11]. 
A total of seven studies were found which included DTDs in decision-analytic model-based 
economic evaluations of statins [12–18]. The DTDs used were typically assumed, rather than 
based on values sourced from the literature, with DTD typically applied in sensitivity 
analysis, with values ranging from 0.00384 (equivalent to 2 weeks of full health traded to 
avoid 10-years on statins) to 0.02 (10 weeks of full health to avoid 10-years on statins). The 
assumed values were often smaller in magnitude than those elicited in empirical studies, 
meaning the impact of DTDs on cost-effectiveness results could have been underestimated. 
Even at the levels assumed the inclusion of DTDs had a marked effect on whether the 
interventions proved to be cost-effective. Often treatment strategies which were highly cost-
effective in the base-case analysis ceased to be cost-effective once DTDs had been integrated, 
although the reporting within the sensitivity analysis was often insufficiently detailed to draw 
firm conclusions. It was clear from the review that there was methodological uncertainty 
regarding the best approach for incorporating DTDs into the QALY and model-based 
economic evaluations. On-going work in the literature, such as the appropriate methods for 
the calculation of joint health state utility values where patients have multiple conditions 
[19,20], could be useful in providing a methodological framework for properly accounting for 
DTDs within the QALY calculation. 
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4. Conclusions 
 
This editorial has suggested the potential need to incorporate DTD into model-based 
economic evaluations of long-term preventative interventions. A review of studies eliciting, 
and using, DTD found evidence of   a measurable and important impact on populations taking 
a preventative medicine. Currently, where DTDs had been included in primary preventative 
model-based economic evaluations, their inclusion could change whether treatments were 
judged to be cost-effective even using values of DTD at the lower range of those found in the 
elicitation studies. The inclusion of DTDs is therefore likely to make it harder for long-term 
medication use to be cost-effective. However, the scope for the inclusion of DTDs should not 
be confined to economic evaluations for long-term preventative interventions and could also 
play an important role in other areas.  Therefore considerations regarding the need for the 
inclusion of DTDs should ideally play a routine role in the conceptualisation stage for model-
based economic evaluations. 
 
There is a need for using appropriate elicitation methods, such as discrete choice 
experiments, in relevant populations to produce robust point estimates of DTDs together with 
a measure of uncertainty around the point estimate. Existing studies for the elicitation of 
DTDs find evidence of heterogeneity in preferences implying that the use of mean population 
values would underestimate and overestimate DTDs for many individuals. Consequently 
classes of individuals should therefore be identified where possible using appropriate 
regression-based methods and reflected in sub-group analysis in model-based evaluations. 
Fundamentally however, the concept requires decision-makers to recognise the potential 
relevance and impact of DTDs in general and for long-term preventative interventions in 
particular.  
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